PUBLICATIONS

THE INTERNATIONAL WHO’S WHO OF LIFE SCIENCES LAWYERS 2014

Who’s Who Legal brings together two of the leading practitioners in the world to discuss key issues facing transactional specialists in the Life Sciences field today.

‫Read More

ANTI CURROPTION REGULATION 2014

The Israeli chapter in the eighth edition of Anti-Corruption Regulation, a volume in the Getting the Deal Through series of annual reports, which provide international analysis in key areas of law and policy for corporate counsel, cross-border legal practitioners and business people.

‫Read More

BUSINESS ASPECTS OF IP

Presentation at a session for legal and IP professionals during a conference of the International Association for the Protection of Intellectual Property, the world’s leading international organization dedicated to the development and improvement of IP.

‫Read More

ANTI CORRUPTION REGULATION 2013

The Israeli chapter in the seventh edition of Anti-Corruption Regulation, a volume in the Getting the Deal Through series of annual reports, which provide international analysis in key areas of law and policy for corporate counsel, cross-border legal practitioners and business people.

‫Read More

ANTI CORRUPTION REGULATION 2012

The Israeli chapter in the sixth edition of Anti-Corruption Regulation, a volume in the Getting the Deal Through series of annual reports, which provide international analysis in key areas of law and policy for corporate counsel, cross-border legal practitioners and business people.

‫Read More

THE INTERNATIONAL WHO’S WHO OF LIFE SCIENCES LAWYERS 2012

The International Who’s Who of Life Sciences Lawyers has brought together three of the
leading practitioners in the world to discuss key issues facing lawyers today

‫Read More

INTELLECTUAL PROPERTY RIGHTS – BIOTECHNOLOGY VERSUS SOFTWARE

The majority of differences between biotechnology licensing agreements and software licensing agreements.

‫Read More

FUNDING AND OPPORTUNITIES OF LIFE SCIENCE COMPANIES

A short brief of the private funding, public funding, and funding supported by the Office of the Chief Scientist of life science companies in Israel , as well as the new rules for IP ownership.
Presentation to the French Delegation at the Chamber of Commerce Israel – France, May 2011

‫Read More

COMPARING BIOTECHNOLOGY AND SOFTWARE LICENSING AGREEMENTS

Software and biotechnology licensing agreements are seemingly similar. However, there are many significant differences arising from the essence of the developed products. What are those differences and how do they affect the negotiation process?

‫Read More

BIOLEGIS

Biolegis – What is it about? Who‘s behind it? What does it provide? What are the client benefits?

‫Read More

FUNDING AND OPPORTUNITIES OF LIFE SCIENCE COMPANIES

A short brief on financing and support opportunities in Israel for the innovation and export of biotechnology

‫Read More

THE STATE OF THE ISRAELI LIFE SCIENCE

Facts about Israeli life science and technology industries and certain business structures
The IBA Technology Conference presentations, February 2011

‫Read More

COMPARING LIFE SCIENCE AND TECHNOLOGY LICENSES

Licensing in biotechnology transactions vs. software transactions – the principle differences
The IBA Technology Conference presentations, February 2011

‫Read More

TECHNOLOGY RIGHTS AND DISTRESSED COMPANIES IN ISRAEL

Presentation of Israeli Law aspects of purchase of technology from distressed companies
The IBA conference, Vancouver October 6, 2010

‫Read More

IP CHALLENGES AND OPPORTUNITIES IN ISRAELI BIOTECH

Presentation to a french delegation comprised of investors and entrepreneurs, aimed to promote collaborations with Israeli investors and entrepreneurs, in the fields of biotechnology, drug development and medical device

‫Read More

COLLABORATIONS AS ALTERNATIVE FINANCING

Various models of collaborations as alternative financing means for biotechnology companies

‫Read More

THE INTERNATIONAL WHO’S WHO OF LIFE SCIENCES LAWYERS

Roundtable – five of the leading practitioners in the world discuss key issues facing lawyers today (in the Life-Sciences field)

‫Read More

RECENT NEWS

Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $9 Million private notes exchange agreement, and a $10 Million private placement of the company’s Secured Convertible Notes.
July 27, 2017

Read more here.

Horn & Co. ranked, again, by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions
June, 2017

Horn & Co. ranked, again, by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions:  “Horn & Co is in its element when commercialising intellectual property; its finely honed business instincts ensure that it can identify the best routes to maximise portfolio value”. Partners Yuval Horn and Ohad Mamann were recommended as leading individuals: “’Yuval and Ohad are among the best corporate attorneys in the country, and have been instrumental securing licence agreements for us,’ enthuses one client”. Read more here: http://www.iam-media.com/patent1000/rankings/Detail.aspx?g=7bebd694-1b48-4d68-bcfa-8668b0003f18

Yuval Horn, Keren Kanir, Ohad Mamann and Tammy Alon of Horn & Co., Law Offices represented Eloxx Pharmaceuticals Ltd. in its Series C financing round and simultaneous entering into an agreement for an acquisition transaction with Sevion Therapeutics, Inc.

Read more here.

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “the firm has been active at the ‘top level’ in the healthcare sector for over 20 years”
April 2017

Read more here

Yuval Horn, Roy Ribon and Yasmin Zohar of Horn & Co. acted as Israeli counsel to Therapix Biosciences Ltd. (NASDAQ: TRPX) (TASE: THXBY), in its listing on Nasdaq and offering of $12 million
March 2017

Read more here

Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2017 ranking by fields of expertise
March 2017

Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2017 ranking by fields of expertise. Firm was ranked a leader (“tier 1”) firm in the field of Hi-Tech, and as an outstanding firm in the fields of Intellectual Property, M&A, Investment Funds and Capital Markets.

See the full rankings here: http://wink.globes.co.il/docs/law2017_table_only.pdf

 

Yuval Horn was noted as one of leading practitioners in Israel in the field of Information Technology by the 2017 edition of Who’s Who Legal: Telecommunications Media & Technology
January 2017

Read more here

Adv. Paz Abercohen joined the firm as a partner
January 2017

Yuval Horn and Ohad Mamann of Horn & Co. represented the investors in ArtsAvit’s financing round, led by Pontifax, Arkin Holdings and Merck Ventures
January 2017

Read more here

Vascular Biogenics Ltd. (NASDAQ:VBLT) Announces $24 Million Registered Direct Offering
December 2016

Read more here

Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $54.1 Million private notes exchange agreement, and a $22.5 Million private placement of the company’s Secured Convertible Notes
December 2016

Read more here

IBA 2nd M&A conference in the technology sector crowned with success
October 2016

The conference, held at the Hilton hotel in Tel-Aviv, was coordinated by Clara Ann Gordon, Yuval Horn and Jocelyn Kelley, and brought together 140 delegates from 35 countries (including 55 from Israel). The conference included a keynote speech by Avi Hasson, the Chief Scientist, panels covering hot topics in both M&A and technology, a joint dinner in Jaffa and several social events.

Yuval Horn participates in the WHO’S WHO LEGAL’S ROUNDTABLE: LIFE SCIENCES 2016
June 2016

Yuval Horn participates in the WHO’S WHO LEGAL’S ROUNDTABLE: LIFE SCIENCES 2016 – bringing together five leading experts to discuss issues facing life sciences lawyers and their clients today.

Read more here

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. in its $24 Million follow-on offering on NASDAQ
June 2016

Read more here

Horn & Co. listed by iam Magazine as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions
May 2016

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions, stating: “Horn & Co is “a great office for licensing”…the group shines at the commercialization of innovative technologies… Hotly tipped for his business acumen, Yuval Horn is a consummate dealmaker”.
Read more here

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round led by Intermountain Healthcare
May 2016

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round led by Intermountain Healthcare, with participation of Dolby Ventures, Ourcrowd, Marc Benioff and Khosla Ventures.

Read more here

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round
May 2016

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round led by Intermountain Healthcare, with participation of Dolby Ventures, Ourcrowd, Marc Benioff and Khosla Ventures.

Read more here

Yuval Horn and Keren Margalit of Horn & Co. represented BioSight Ltd. in its Series B financing round led by Arkin Holdings and US based venture firm Primera Capital
May 2016

Read more here

Yuval Horn to moderate the corporate finance panel at the IBA 4th Annual World Life Sciences Conference on July 3, 2016 in San Francisco
May 2016

For more information: IBA 4th Annual World Life Sciences Conference

Yuval Horn and Ohad Mamann of Horn & Co. represented the lead investors in cancer metabolism start-up Metabomed’s series A financing round
April 2016

Yuval Horn and Ohad Mamann of Horn & Co. represented the lead investors in cancer metabolism start-up Metabomed’s series A financing round, led by Pontifax and Arkin Holdings, and including the venture arms of Merck, Boehringer Ingelheim and Pfizer and the Technion Research and Development Foundation.

For more information: http://www.globes.co.il/en/article-cancer-metabolism-co-metabomed-raises-18m-1001114888

Yuval Horn will co-chair the 2nd Annual Mergers and Acquisitions in the Technology Sector Conference of the International Bar Association, to take place on October 27-28, 2016 in Tel Aviv
April 2016

The annual conference brings together professionals from leading international law firms, to debate the hottest issues in M&A in the technology industry.

For more information: http://www.ibanet.org/Article/Detail.aspx?ArticleUid=f22720f1-f644-4225-9368-07c59730179a

Adv. Orly Sternfeld joined the firm as a partner
January 2016

Yuval Horn to participate in an Executive Briefing about: Risks and Rewards of Expanding into the United States, on January 31, 2016
January 2016

Yuval Horn will participate in an Executive Briefing to be hosted by the Israel-America Chamber of Commerce and Mintz Levin about: Risks and Rewards of Expanding into the United States, on January 31, 2016.

Read more here.

Yuval Horn and Orly Sternfeld of Horn & Co. advised Zebra Medical Vision Ltd. in its collaboration agreement with Dell Services to enable next-generation clinical insights and better population health management
November 2015

Read more: http://www.businesswire.com/news/home/20151124005037/en/Dell-Services-Leverages-Big-Data-Analytics-Cloud

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. in its $15 Million follow-on offering on NASDAQ
November 2015

Read more here: VBL follow-on offering

Yuval Horn was announced as the incoming Co-Chair of the International Bar Association Technology Law Committee
October 2015

Yuval Horn was announced as the incoming Co-Chair of the International Bar Association Technology Law Committee, effective January 1, 2016, for 2 years. The Committee includes 600 professionals from many countries with expertise in technology related transactions of all types. Its subcommittees include specialty focus on outsourcing, life sciences, internet business, corporate information, and disputes and rights. Yuval is the 3rd Israeli to have been elected as a Chairperson of any professional committee of the IBA. http://www.ibanet.org/LPD/IP_Comm_Tech_Section/Technology_Law/Default.aspx

Yuval Horn to moderate a panel relating to Regulation of Genetic Testing at the IBA Annual Conference in Vienna in October, 2015
September 2015

Horn & Co. represented cCam Biotherapeutics Ltd. and its shareholders in the acquisition by Merck Sharp & Dohme for $605 million.
July 2015

Read more about it here:

http://www.businesswire.com/news/home/20150728005731/en/Merck-Enhances-Immuno-Oncology-Portfolio-Acqu#.Vbd1sPmqqko

Taboola.com increases its $117 million private financing round, and closes follow-on investments with Baidu Inc. and DailyMail.com.
June 2015

http://blogs.wsj.com/digits/2015/05/18/baidu-invests-in-content-recommendation-company-taboola

http://blogs.wsj.com/cmo/2015/06/04/dailymail-com-invests-3-million-in-web-content-marketing-firm-taboola/

 

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.
June 2015

http://www.iam-media.com/Patent1000/Rankings/Detail.aspx?g=ceb9f83d-2e12-4d12-a80d-d9077e16ad23

Biolight Israeli Life Sciences Investments Ltd (TASE: BOLT) executes memorandum for strategic cooperation in China and closes $6.2 million investment with investors based in Hong Kong.
May 2015

Angioslide Ltd. closes a strategic license agreement for the Asian market and round D investment round with a consortium of Chinese investors.
April 2015

Polyheal Ltd. enters into a manufacturing and distribution license agreement with Praxis Pharmaceutical S.A.
April 2015

Intec Pharma Ltd. enters into a Research, Option and Licensing Agreement with one of the world’s top 20 pharmaceutical companies, in terms of market cap.
April 2015

http://intecpharma.com/press-release/signing-of-an-agreement-with-a-global-pharmaceutical-company

 

Cellera, Inc. closes asset purchase agreement for undisclosed amount
March 2015

Yuval Horn will co chair the keynote and corporate finance panels at the upcoming IBA World Life Sciences Conference on June 12 in Philadephia
March 2015

Philadelphia Conference- IBA- June 2015

Yuval Horn to co chair the keynote 5/10 Trend panel: “what are the emerging life sciences business models and what will they look like in five years and ten years from now?” at the IBA 3rd World Life sciences Conference.

 

In addition, Yuval will co chair the Panel: “Financing life sciences companies whats current and whats new”.

Taboola.com closes $117 million private financing round
February 2015

Read more about it here: http://blogs.wsj.com/digits/2015/02/04/content-marketing-company-taboola-raises-117-million/?KEYWORDS=taboola

Adv. Roy Ribon and Adv. Ohad Mamann joined the firm as partners
January 2015

Yuval Horn nominated Vice Chairman of the International Bar Association Technology Law Committee.
December 2014

Medivation Inc. (represented by Horn & Co.) Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd.
October 2014

Read more here: http://investors.medivation.com/releasedetail.cfm?ReleaseID=877968

Yuval Horn will moderate a panel at the upcoming IBA Annual Conference in Tokyo, Japan (October 2014).
October 2014

Yuval Horn will moderate a panel, titled “Telemedicine by satellite: improving health care and creating legal and ethical issues”, at the IBA’S UPCOMING ANNUAL CONFERENCE IN TOKYO, JAPAN.

Yuval Horn will join a panel at the upcoming IBA Annual Conference in Tokyo, Japan (October 2014).
October 2014

Yuval Horn will join a panel on “License to Kill” in the upcoming International Bar Association Annual conference in Tokyo on October 22, 2014.

Amnon Ovadia (Babylon Software Ltd.) purchases the translation business from Babylon Ltd. (TASE)
September, 2014

Amnon Ovadia (Babylon Software Ltd.) purchases the translation business from Babylon Ltd. (TASE)

V-Gen Ltd.’s shareholders sell all of their shares to Newport Corporation.
July 2014

V-Gen Ltd.’s shareholders sign an agreement for the sale of all of their shares to Newport Corporation.

Vascular Biogenics Ltd. announced the pricing of its initial public offering.
July 2014

Vascular Biogenics Ltd. announced the pricing of its initial public offering. The shares are scheduled to begin trading on the NASDAQ Global Market on July 31, 2014 under the ticker symbol “VBLX.” The offering is expected to close on August 5, 2014, subject to customary closing conditions.

Horn & Co. listed by iam Magazine as one of the top 6 recommended Israeli firms in the field of IP transactions.
June 2014

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of IP transactions

Content discovery business Taboola strikes deal with Yahoo Japan
June 2014

Content discovery business Taboola strikes deal with Yahoo Japan

WE MOVED. Our new offices are located at…
April 2014

WE MOVED.
Our new offices are located at:
Amot Investments Tower
2 Weizmann St., 24th Floor
Tel Aviv 6423902, Israel

Yuval Horn participates in the Who’s Who Legal’s Roundtable: Life Sciences 2014.
March 2014

Yuval Horn participates in the WHO’S WHO LEGAL’S ROUNDTABLE: LIFE SCIENCES 2014: TRANSACTIONAL – Who’s Who Legal brings together two of the leading practitioners in the world to discuss key issues facing transactional specialists today.

Yuval Horn will chair the Keynote Panel at the 2nd Annual IBA World Life Sciences Meeting.
February 2014

Yuval Horn will chair the Keynote Panel at the 2ND ANNUAL IBA WORLD LIFE SCIENCES MEETING, IN JUNE 2014, SAN DIEGO, CA USA. The Keynote Panel is titled “5/10 Trend Panel – what are the emerging life sciences business models and what will they look like in 5 years and 10 years from now?”

CollPlant Holdings Ltd. completes a public offering.
December 2013

Read more here: http://www.themarker.com/markets/1.2198545

Horn & Co. assisted the public companies association in outlining a proposed modification to the guidelines for disclosure of biomed companies.
December 2013

Disclosure requirements and analysis model for biomed companies – Horn & Co. assisted the public companies association in outlining a proposed modification to the guidelines for disclosure of biomed companies, at a conference held at the Tel-Aviv Stock Exchange on December 23, 2013.

Yuval Horn to co-chair a panel at the upcoming IBA Annual Conference in Boston (October 2013).
September 2013

Yuval Horn to co-chair a panel on “Building a Winning Team in Technology Companies” at the upcoming International Bar Association Annual Conference on October 9, 2013 in Boston

Immune Pharmaceuticals Ltd. completes its merger with the US publicly traded company Immune Pharmaceuticals Inc.
August 2013

Immune Pharmaceuticals Ltd., a privately held Israeli company, completes its merger with the US publicly traded company Immune Pharmaceuticals Inc. (formerly known as EpiCept Corporation) (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD).

VIM Technologies Ltd. is acquired by Presstek (Israel) Ltd.
August 2013

VIM Technologies Ltd. is acquired by Presstek (Israel) Ltd.

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.
August 2013

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.

Horn & Co. Represents the Israeli Public Companies Organization in its dialogue with the ISA.
May 2013

Read more here: http://www.globes.co.il/news/article.aspx?did=1000839127

Yuval Horn to co-chair a panel at the IBA World Life Sciences Conference in Dallas, Texas.
May 2013

Yuval Horn to co-chair a panel on Tech Transfer Tactics at the IBA World Life Sciences Conference in Dallas, Texas, USA ( IBA LIFE SCIENCES CONFERENCE)

Yuval Horn noted as one of the 5 worldwide leading practitioners in Life Sciences Transactions.
April 2013

The 2013 editorial of the Who’s Who Life Sciences notes Yuval Horn as one of the 5 worldwide leading practitioners in Life Sciences Transactions and states: “Yuval Horn of Horn & Co. Law Offices in Israel was repeatedly cited as ‘the best in the market’. He is well versed in all transactional aspects of the sector, including licensing and sale of technology, joint ventures and other commercial transactions”

Chambers Global ranks Yuval Horn as a leading Israeli practitioner in M&A: High Tech
March 2013

Chambers Global ranks Yuval Horn as a leading Israeli practitioner in M&A: High Tech

Yuval Horn nominated as Chairperson of the IBA LifeSciences SubCommittee.
December 2012

Yuval Horn nominated as Chairperson of the IBA LifeSciences SubCommittee.

Immune Pharmaceuticals Ltd., and EpiCept Corporation entere into a definitive merger agreement.
November 8, 2012

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation (NASDAQ OMX Stockholm Exchange and OTCQX: EPCT) today announced that they have entered into a definitive merger agreement.

Yuval Horn chairs a panel at the IBA Annual Conference in Dublin, Ireland (October 2012).
October, 2012

Double Irish Licensing Agreements – Yuval Horn chairs a panel with respect to Double Irish structures at the IBA Annual Conference in Dublin, Ireland (IBA ANNUALCONFERENCE).

ILS Brokers Ltd.’s shareholders sell all of their shares to Leader Capital Markets Ltd.
May, 2012

ILS Brokers Ltd. signs an agreement for the sale of all of its shares to Leader Capital Markets Ltd., in consideration for 10% of Leader’s shares and NIS 10 million.

Pfizer, Inc. and Protalix BioTherapeutics, Inc. announce that the FDA approved ELELYSO™.
May, 2012

New York, NY/Carmiel, Israel, May 1, 2012 – Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease.

Protalix BioTherapeutics, Inc. raised over $25 million on AMEX.
February, 2012

Protalix BioTherapeutics, Inc. raised over $25 million following the sale of approximately 5 million shares on AMEX.

A merger of Gardia Medical Ltd. with Allium Medical Solutions Ltd.
January, 2012

A merger of Gardia Medical Ltd. (“Gardia”), a private company controlled by the venture capital funds group Medica Venture Partners, with Allium Medical Solutions Ltd. (“Allium”), in which all of the issued capital of Gardia was acquired. As part of the agreement, Allium shall invest at least US$ 3.5 million in the development of Gardia’s products, which regard to various solutions to emboli formed during catheterization.

Yuval Horn elected as an expert in Life Sciences by Who’s Who of Life Sciences Lawyers 2012.
November, 2011

Yuval Horn elected as an expert in Life Sciences by Who’s Who of Life Sciences Lawyers 2012.

Vision BI shareholders sell controlling interest to Keyrus, SA.
October, 2011

Vision BI shareholders sell controlling interest to Keyrus, SA.

Completion of a merger of IBI Biomedical Innovations Ltd. with Allium Medical Solutions Ltd.
September 8, 2011

Completion of a merger of IBI Biomedical Innovations Ltd. (“IBI”) with Allium Medical Solutions Ltd. (“Allium”) in which all of the issued capital of IBI was acquired in consideration for 49.93% of the issued and paid up capital of Allium and its voting rights. In addition, Allium had allocated to IBI employees, consultants and officers non-negotiable option warrants.

Gefen Biomed Investments Ltd. files Shelf Prospectus with ISA.
August 22, 2011

Gefen Biomed Investments Ltd. files Shelf Prospectus with Israel Securities Authority.

Yuval Horn speaks at a dinner party for the French Delegation to THE ILSI-BIOMED 2011 CONFERENCE
May, 2011

Yuval Horn speaks at a dinner party for the French Delegation to THE ILSI-BIOMED 2011 CONFERENCE hosted by the Chamber of Commerce Israel – France.